Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.820
-0.030 (-1.62%)
At close: Feb 21, 2025, 4:00 PM
1.840
+0.020 (1.10%)
After-hours: Feb 21, 2025, 7:59 PM EST
Esperion Therapeutics Revenue
Esperion Therapeutics had revenue of $51.63M in the quarter ending September 30, 2024, with 52.00% growth. This brings the company's revenue in the last twelve months to $295.45M, up 187.12% year-over-year. In the year 2023, Esperion Therapeutics had annual revenue of $116.33M with 54.14% growth.
Revenue (ttm)
$295.45M
Revenue Growth
+187.12%
P/S Ratio
1.03
Revenue / Employee
$1,231,046
Employees
240
Market Cap
358.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 116.33M | 40.86M | 54.14% |
| Dec 31, 2022 | 75.48M | -2.97M | -3.79% |
| Dec 31, 2021 | 78.45M | -149.10M | -65.52% |
| Dec 31, 2020 | 227.55M | 79.18M | 53.37% |
| Dec 31, 2019 | 148.36M | - | - |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ESPR News
- 4 days ago - Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4 - GlobeNewsWire
- 8 days ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions - GlobeNewsWire
- 2 months ago - Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone + - Seeking Alpha
- 2 months ago - Esperion Announces $210 Million Convertible Debt Financing - GlobeNewsWire
- 2 months ago - Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel - GlobeNewsWire
- 2 months ago - Will The Long Awaited Breakout For Esperion Therapeutics Hold? - Seeking Alpha
- 3 months ago - Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 - GlobeNewsWire